Literature DB >> 29936679

Author's Reply to Reith: "Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults".

Anne van Rongen1, Johannes N van den Anker2,3,4, Catherijne A J Knibbe5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29936679     DOI： 10.1007/s40262-018-0692-z

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  11 in total

1.  Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers.

Authors:  Margreke J E Brill; Anne van Rongen; Aletta P I Houwink; Jacobus Burggraaf; Bert van Ramshorst; René J Wiezer; Eric P A van Dongen; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2014-10       Impact factor: 6.447

2.  Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam.

Authors:  Stacy S Shord; Lingtak-Neander Chan; Joseph R Camp; Eva M Vasquez; Hyun-Young Jeong; Robert E Molokie; Charles L Baum; Hui Xie
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

3.  Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects.

Authors:  J M van Gerven; G Roncari; R C Schoemaker; J Massarella; P Keesmaat; H Kooyman; P Heizmann; M Zell; A F Cohen; J Dingemanse
Journal:  Br J Clin Pharmacol       Date:  1997-11       Impact factor: 4.335

4.  Higher Midazolam Clearance in Obese Adolescents Compared with Morbidly Obese Adults.

Authors:  Anne van Rongen; Margreke J E Brill; Janelle D Vaughns; Pyry A J Välitalo; Eric P A van Dongen; Bert van Ramshorst; Jeffrey S Barrett; Johannes N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

5.  Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

Authors:  J C Gorski; S D Hall; D R Jones; M VandenBranden; S A Wrighton
Journal:  Biochem Pharmacol       Date:  1994-04-29       Impact factor: 5.858

6.  Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism.

Authors:  K E Thummel; D O'Shea; M F Paine; D D Shen; K L Kunze; J D Perkins; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1996-05       Impact factor: 6.875

7.  Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.

Authors:  Jang-Ik Lee; Diego Chaves-Gnecco; Janet A Amico; Patricia D Kroboth; John W Wilson; Reginald F Frye
Journal:  Clin Pharmacol Ther       Date:  2002-12       Impact factor: 6.875

8.  Effect of age, gender, and obesity on midazolam kinetics.

Authors:  D J Greenblatt; D R Abernethy; A Locniskar; J S Harmatz; R A Limjuco; R I Shader
Journal:  Anesthesiology       Date:  1984-07       Impact factor: 7.892

9.  The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery.

Authors:  Margreke J Brill; Anne van Rongen; Eric P van Dongen; Bert van Ramshorst; Eric J Hazebroek; Adam S Darwich; Amin Rostami-Hodjegan; Catherijne A Knibbe
Journal:  Pharm Res       Date:  2015-07-23       Impact factor: 4.200

10.  Changes in duration of action of rocuronium following decrease in hepatic blood flow during pneumoperitoneum for laparoscopic gynaecological surgery.

Authors:  Yang Liu; Wen Cao; Yu Liu; Yun Wang; Ren Lang; Yun Yue; An-Shi Wu
Journal:  BMC Anesthesiol       Date:  2017-03-20       Impact factor: 2.217
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.